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De Novo Infection in a Renal
Infection with hepatitis B virus (HBV) can be prevented by vaccination with the major HBV surface (HBs) antigen (Ag) [1] . However, HBV isolates carrying mutations within the adeterminant have changed HBs antigenicity and are able to escape immune control and cause infection in vaccinated persons [2, 3] . HBV mutants may also emerge in liver transplant recipients and in infants receiving anti-HBs hyperimmunoglobulin as immunoprophylaxis [4, 5] . Furthermore, HBV mutants are present in chronically HBV-infected patients who do not receive medical treatment, which implies that these mutants circulate naturally and present a source of de novo HBV infection [6, 7] . Therefore, some patients with a compromised immune system, such as transplant recipients, may be at high risk of HBV infection. For example, an HBV mutant with an amino acid substitution at position 133M in the HBsAg caused HBV infection in a liver transplant recipient, even though this patient was vaccinated and had a high titer of anti-HBs [8] .
Here, we report that HBV mutants are able to escape immune responses against hepatitis B vaccines and to establish chronic infection in a transplant recipient. These HBV mutants carried multiple amino acid substitutions around and within the HBsAg a-determinant and showed reduced reactivity to a panel of anti-HBs antibodies. Furthermore, we used DNA immunization of mice with plasmids expressing wild-type (wt) and mutant HBsAg to characterize the immunogenicity of wt and mutant HBsAg [9, 10] . We concluded that the antigenicity and immunogenicity of mutant HBsAg were significantly changed and thus led to immunity escape.
Materials and methods.
A renal transplant recipient was tested during routine diagnostic surveillance for HBV infection (figure 1). The serological profile (positive for anti-HBs and negative for anti-HBV core antigen [HBc], anti-HBV e antigen [HBe], HBsAg, and HBeAg) indicated that this patient was successfully immunized against HBV and had not been exposed to HBV infection prior to transplantation. Antibodies to human immunodeficiency virus and hepatitis C virus were not detected. Monitoring was continued routinely after the diagnosis of chronic HBV infection, at intervals of 1 year and, later, of 6 months. HBV DNA was detected by routine diagnostic polymerase chain reaction (PCR) and bDNA assay (Chiron).
DNA extraction, PCR amplification of the encoding region of HBsAg (nt 157-860), and cloning and sequencing of PCR fragments were done as described elsewhere [10] . The rate of nucleotide misincorporation was ∼10 Ϫ5 nt/base/cycle under our PCR conditions, resulting in 1 PCR error/3300 bp. The HBsAg sequences containing mutations were recloned into the expression vector pcDNA3 and tested for the expression of HBsAg by transient transfection in baby hamster kidney or HepG2 cells, as described elsewhere [10] . For immunoprecipitation (IP), transfected cells were cultured in medium supplemented with 10% dialyzed fetal calf serum and 20 mL/mL SDS-PAGE. Immunofluorescence (IF) staining of transfected cells using polyclonal antibodies and MAbs was done as described by Zheng et al. [10] . A commercial HBsAg ELISA assay (Enzygnost HBsAg 5.0; Dade Behring) was used for detection of HBsAg in culture supernatants of transfected cells, according to the manufacturer's instructions.
Immunization of BALB/cJ (H-2L d ) mice with plasmid DNA was done as described elsewhere [9, 10] . The mice received a total of 3 immunizations 3 weeks apart and were killed 3 weeks after the last immunization. Anti-HBs antibodies in serum samples were detected by use of an Enzygnost anti-HBs II kit (Behring), according to the manufacturer's instructions. To detect cytotoxic T lymphocyte (CTL) responses to HBsAg, splenocytes of immunized mice were cultured with P815 cells expressing HBsAg (kindly provided by Dr. F. V. Chisari, Scripps Research Institute, La Jolla, CA) for 5 days. HBsAg-specific CTLs were detected by chromium release assay using 51 Cr-labeled P815 target cells [9] . IgG was added to 200 mL of splenocytes and incubated at 4ЊC for 1 h. After 3 washes, splenocytes were incubated with 2 mL of anti-CD8a fluorescein isothiocyanate (clone 53-6.7) and 2 mL of phycoerythrin-labeled anti-mouse IgG1. All antibodies used in these experiments were purchased from BD Biosciences. After staining with labeled antibodies, cells were washed twice, resuspended in 0.5 mL of staining buffer in a tube, and subjected to flow cytometry.
Results.
Before renal transplantation (month Ϫ36 to month 0), the patient was positive for anti-HBs, with titers of 25-40 U/mL, but was negative for HBsAg, HBeAg, anti-HBc, and anti-HBe (figure 1). HBeAg appeared for the first time 25 months after renal transplantation, followed by other parameters, such as anti-HBc, HBsAg, and HBV DNA, which indicates that a persistent HBV infection occurred in this patient. HBV DNA concentrations increased from 520 to 1400 pg/mL between months 48 and 68. Anti-HBs became undetectable at month 58. Thus, a de novo infection with HBV occurred despite the presence of anti-HBs at a protective level. The source of HBV infection for this patient was not known.
Analysis of the coding region of HBsAg of HBV isolates from this patient at months 51, 58, and 68 after transplantation revealed that heterogeneous HBV populations with different variants were present (figure 1). A mutant K33 was present in all 3 samples analyzed up to month 68 and was predominant by month 68. Two other mutants, K29 and K30, were found in 2 different samples, whereas 1 mutant, K07, was found only 
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The percentage of dimer-positive CD8 ϩ cells is given. The CD8 ϩ cells were 43%-75% of total cell counts. The unspecific staining of CD8 ϩ cells with control dimers is !3%. in 1 sample from month 51. All isolates were closely related to the HBV genotype D [11] . These variants carried multiple mutations at amino acid positions 118, 120, 126, 127, 130, 134, 144, and 160 of HBsAg. Mutant types K07, K29, and K30 harbored amino acid substitutions T118R, P120A, P127T, and G130K within the HBsAg a-determinant and K160N, a determinant for HBV subtypes. These 3 mutants differed from each other at amino acid positions 126 (S or I), 130 (N or K), and 144 (D or E). Variations at 7 positions-P120T, G130R, and F137H in particular-were found in mutant type K33 but not in naturally occurring HBV isolates. K33 had a lysine (K) at position 160 of the amino acid sequence, corresponding to the ayw2 subtype [11, 12] . No wt HBV isolate was found among sequenced clones, indicating that these mutants were competent for replication, despite variations in the HBV polymerase sequences (data not shown). The HBV load reached copies/mL, as determined by the bDNA assay. A pop- and K33. These results indicate that mutant HBsAg had a reduced ability to induce anti-HBs antibody in mice.
The amino acid substitutions found in mutant HBsAg are not supposed to affect the induction of HBsAg-specific CTL responses. Consistently, immunized mice developed CTL responses to HBsAg without an obvious difference between these different groups, as tested in chromium release assay (table 1) Discussion. In the present study, we documented an unusual case of de novo HBV infection in an adult that occurred despite preexisting protective antibody. Our data indicate that a persistent HBV infection was established with a heterogeneous population of HBV variants carrying several novel mutations within the HBsAg a-determinant [13] . In particular, the K160N substitution has been found once by examination of a sample of subtype ad, which is devoid of the w or r determinant [14] . The selection of the mutation at aa 160 of HBsAg suggests that subtype W-specific antibodies to HBsAg may be able to neutralize HBV.
DNA immunization was found to be a useful tool for assessing the immunogenicity of mutated HBsAg. We demonstrated that the immunogenicity of mutant HBsAgs was significantly impaired, even though their antigenicity was only partly reduced. Mutant HBsAg did not stimulate an increased production of anti-HBs in the patient we studied.
The immunological control of HBV is achieved by both B and T cell responses [15] . Immunosuppressive treatment after organ transplantation apparently leads to an impairment of T cell functions and allows HBV mutants to escape the protective antibody responses. Thus, transplant recipients may be at risk for infection with HBV mutants despite prior vaccination.
